DS
TBRA

David Shaw’s Tobira Therapeutics, Inc. Common Stock TBRA Stock Holding History

David Shaw’s Portfolio TBRA Stock Details TBRA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q2 		– Sell
-2,248
Closed -$25K – 3998
2015
Q1 		$25K Buy
+2,248
New +$24.1K ﹤0.01% 3568

Other funds holding TBRA

NHAS
Novo Holdings A/S Hellerup, Denmark $1.72B AUM 106.92% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
CPV
Canaan Partners VII Westport, Connecticut $32.3M AUM 154.97% 1-Year Est. Return
A
Abingworth London, United Kingdom $307M AUM 93.47% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $767M AUM 119.71% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.14% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

David Shaw's TBRA Position: Q2 2015 in Review

David Shaw sold out of Tobira Therapeutics, Inc. Common Stock (TBRA) in Q2 2015, closing a stake of 2,248 shares — an estimated $25K sold.

David Shaw first reported a position in TBRA in Q1 2015 and held it in 1 quarter. The position peaked at $25K in Q1 2015. 42 funds tracked by Wall St. Rank hold TBRA as of Q2 2015.

  • David Shaw reported no remaining Tobira Therapeutics, Inc. Common Stock position as of Q2 2015 after selling out during the quarter.
  • David Shaw sold 2,248 Tobira Therapeutics, Inc. Common Stock shares in Q2 2015, an estimated $25K.
  • David Shaw first reported a position in Tobira Therapeutics, Inc. Common Stock in Q1 2015 and held it in 1 quarter.
  • David Shaw's Tobira Therapeutics, Inc. Common Stock position peaked at $25K in Q1 2015.
  • 42 funds tracked by Wall St. Rank held Tobira Therapeutics, Inc. Common Stock as of Q2 2015.

Based on D.E. Shaw & Co's 13F filing for Q2 2015, filed 14 Aug 2015.